Kumu nahele: yaozhi.com 3282 0
Introduction: e like me ka ʻikepili lapaʻau hou loa, hiki i ka molnupiravir ke hōʻemi i ka helu o ka hale maʻi a i ʻole ka make ma 30%.
Ma Nowemapa 30, ua koho ka pane FDA i ka 13:10 e ʻae i ka noi EUA no ka molnupiravir, kahi lāʻau waha hou o MSD.Inā ʻae ʻia, ʻoiai aia ka ʻōlelo a ke kauka, hiki i nā poʻe maʻi i hōʻoia ʻia a i ʻole ka poʻe i hōʻike ʻia i ka maʻi maʻi hiki ke hoʻohana i ka lāʻau lapaʻau ma ka home me ka hele ʻole i ka haukapila a i ʻole ke kauka no ka mālama ʻana e like me nā lāʻau antibody monoclonal.
ʻO Molnupiravir kahi lāʻau lei aliʻi hou i hoʻomohala ʻia e mosadon i ka hui pū ʻana me ka hui biotherapy ʻo Ridgeback.Ua loaʻa mua iā ia ka ʻae ʻana i ka hoʻohana ʻana i ka pilikia ma UK, akā ʻo ka hōʻike hōʻike hōʻike hōʻike hou loa i hōʻike ʻia ua emi nui ka helu kūpono.
Wahi a ka hoʻolaha a MSD i ka pule i hala aku nei, ua hōʻike ʻia nā hopena hōʻike hope loa he 68 poʻe ma ka hui placebo 699 i mālama ʻia i ka haukapila a i make paha, ʻoiai he 48 wale nō o nā mea maʻi 709 e lawe ana i ka monapiravir i hōʻemi hou ʻia, ka mea i hōʻemi i ka pilikia o ka haukapila / make mai 9.7% a 6.8%, a hiki i ka 30%.He mea kūpono ke haʻi ʻia he 9 mau kānaka i make i ka hui placebo a ʻo 1 wale nō ma ka hui molnupiravir.
Eia nō naʻe, ua koho ke komite loea US FDA i ka 13 a i ka 10 e kākoʻo i ka molnupiravir, kahi lāʻau antiviral o ka methadone, e ʻōlelo ana ua ʻoi aku nā pōmaikaʻi ma mua o nā pilikia.ʻAʻole koi ʻia ʻo FDA e hahai i nā ʻōlelo a ke komite, akā koho maʻamau e hahai iā lākou.
Eia kekahi, ke ʻimi nei ʻo Pfizer i ka ʻae ʻana o FDA no kāna lāʻau lei aliʻi hou.Hōʻike ka haʻawina hauʻoli o ka pae III o ka paxlovid, kahi lāʻau lapaʻau waha lei aliʻi hou, hiki ke hōʻemi ʻia ka pilikia o ka hale maʻi a i ʻole ka make ma kahi o 89% i nā poʻe maʻi me ka lei aliʻi hou i loko o ʻekolu mau lā o ka maʻi, e hoʻohālikelike ʻia me ka hopena therapeutic. no ka pale ʻana i ka antibody o ka lei aliʻi hou.
Ka manawa hoʻouna: Dec-17-2021